Read More: MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
Omeros reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.\n<\/p>\n
The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk.The company\u2019s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in December.The company is now looking forward to an approval for the therapy from the European Medicines Agency by mid-2026.<\/p>\n
Shares of Omeros Corporation (OMER) rose 5% after hours on Tuesday after the company expressed optimism for its deal with Danish drugmaker Novo Nordisk and regarding its other drugs.<\/p>\n
The company reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.<\/p>\n
Omeros Corp Deal With Novo<\/p>\n
The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. Under the deal valued up to $2.1 billion, the Danish drugmaker received exclusive global rights in all indications to develop and commercialize Omeros\u2019s zaltenibart and certain related antibodies and products.<\/p>\n
The transaction was closed in November, triggering an upfront cash payment of $240 million. The company is now eligible to receive milestone payments and tiered royalties on annual global net sales of applicable products. \u00a0<\/p>\n
Remaining Lineup<\/p>\n
The company\u2019s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and in children ages two years and older in December. Commercial distribution and sales of Yartemlea in the U.S. began in January. The drug is now being prescribed to both adult and pediatric patients across both hospital and outpatient settings, the company said, while adding that it has engaged several of its workforce to engage directly with transplant centers across the United States.<\/p>\n
The company is now looking forward to an approval for the therapy from the European Medicine Agency by mid-2026.<\/p>\n
\u201cFollowing FDA approval of Yartemlea with a broad label and no boxed warning, REMS, or required vaccinations, our commercial launch is well underway, and patients who urgently need the drug are now able to access it,\u201d said Omeros CEO Gregory A. Demopulos. \u201cOur partnership with Novo Nordisk expands the breadth of indications being pursued for zaltenibart and has provided \u2014 and should continue to provide \u2014 substantial operating capital… These successes are expected to fuel the development of a growing portfolio of commercial products from our robust pipeline as we target positive cash flow in 2027.\u201d<\/p>\n
How Omeros Corp Retail Traders React?<\/p>\n
On Stocktwits, retail sentiment around OMER stock jumped from \u2018bullish\u2019 to \u2018extremely bullish\u2019 territory over the past 24 hours, while message volume increased from \u2018high\u2019 to \u2018extremely high\u2019 levels.<\/p>\n
A Stocktwits user expressed optimism for the stock rallying on the next trading day.<\/p>\n
Another user expressed optimism for Yartemlea, particularly if it gets approval in the EU.<\/p>\n
OMER stock<\/a> has gained 28% over the past 12 months.\u00a0<\/p>\n Read More: MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n